Trial site
The First Affiliated Hospital of Henan Medical University
Xinxiang, Henan 453100, ChinaNot linked to an institution yet
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 1/21 trial
- Phase 21 trial
- Phase 2/31 trial
- Status
- Recruiting10 trials
- Not yet recruiting5 trials
- Active, not recruiting2 trials
- Lead sponsor
- Bristol-Myers Squibb2 trials
- Capital Medical University2 trials
- Antengene Biologics Limited1 trial
- ArriVent BioPharma, Inc.1 trial
- Beijing Tiantan Hospital1 trial
- and 10 more
Running trials
Not yet recruiting
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193· Phase 3· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: xiangyu Ma
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Weizheng Kou
Recruiting
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680· Phase 2· Bristol-Myers Squibb· Source
Contact: Ying-Hua Ji, Site 0152
Recruiting
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
NCT07692165· Phase 1/2· Innatus Therapeutics (Shanghai) Co., Ltd.· Source
Contact: Huang
Recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
NCT07509645· Phase 3· Capital Medical University· Source
Contact: Hongkai Cui
Not yet recruiting
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
NCT07242599· Phase 3· Beijing Tiantan Hospital· Source
Contact: Jianhua Zhao
Recruiting
Screening for Biomarkers of Osteoarthritis
NCT07544823· The First Affiliated Hospital of Xinxiang Medical College· Source
Contact: Tan Lu
Recruiting
Exergames-acceptance and Commitment Therapy(e-ACT) for Breast Cancer Depression and Anxiety: A Randomized Controlled Trial
NCT07721753· Universiti Sains Malaysia· Source
Contact: Lifang zhang
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Active, not recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776· Phase 3· Capital Medical University· Source
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· Phase 3· Celcuity Inc· Source
Contact: Nadene Zack, MS
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Contact: Yinghua Ji, Site 0494
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· Phase 3· BioNTech SE· Source
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source
Contact: Yinghua Ji
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Yinghua Ji, Site 0420
Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888· Phase 2/3· Hutchmed· Source
Contact: Yinghua Ji
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error